University Home | Hospital | Pulse Employment | Contact Us | Search | News 
Thomas Jefferson University Search Jefferson
Jefferson Medical College Jefferson College of Graduate Studies Jefferson College of Health Professions
Thomas Jefferson University - Jonathan R Brody
Jonathan R Brody

Thomas Jefferson University
Jefferson Medical College
Department of Surgery
Division of Surgical Research
Assistant Professor

Director of Surgical Research
Member, Kimmel Cancer Center
Mailing Address
1015 Walnut Street, Curtis 611A
Philadelphia, Pennsylvania 19107
United States
Contact Information
Phone: 215-955-2693
PhD, Johns Hopkins University School of Medicine

Post-doctoral Oncology Fellowship with Scott Kern, MD, Johns Hopkins University

PanCAN-AACR Career Development Award, 2010
Expertise and Research Interests
The main focus of Dr. Brody's laboratory is to find novel therapeutic strategies for pancreatic cancer patients. During his over ten years of training at Johns Hopkins University, Dr. Brody began exploring drug-target interactions. Utilizing diverse molecular biology techniques that include DNA sequencing, gene knockout and silencing assays, and development of a drug metabolism assay, Dr. Brody has published extensively on aspects of chemotherapeutics, namely gemcitabine, 5-fluorouracil and platinum-based agents. Part of this work includes his special interest in targeting cancer cells with defects in the BRCA2/Fanconi Anemia pathway. His work also includes the advancement in the basic DNA detection technique of DNA electrophoresis, by discovering new and better alternatives to tris-based buffers, such as lithium-based buffers, that can separate DNA at a fraction of the time compared to conventionally used conductive media. In regards to mRNA stability, Dr. Brody aided in cloning members of the pp32 gene family over a decade ago. Members of this family, pp32 and APRIL, have been shown previously to be ligands and functionally interact with the RNA binding protein, HuR. Currently, Dr. Brody's work focuses on how HuR biology is involved in pancreatic tumorigenesis as well as cancer cell survival. His laboratory is also interested in how HuR expression levels and protein subcellular localization affects treatment of pancreatic cancer. Recently, the group published work showing that HuR subcellular localization is a valuable predictive marker for the standard of care (i.e., gemcitabine) for this disease. His laboratory's work is now primarily focused on HuR biology as it relates to the clinical management of cancer, including identifying clinically relevant HuR targets. Besides his laboratory work, Dr. Brody was recently named Director of Surgical Research and is Co-director of the Jefferson Pancreas, Biliary and Related Cancer Center at Thomas Jefferson University. He recently won the national PanCAN-AACR Career Development award and an American Cancer Society, Research Scholar Grant for his work on HuR's role in pancreatic cancer.

Patent Dramatically Improves DNA Analysis

(Published 7-16-2007) A basic scientist in the Department of Surgery at Jefferson Medical College and the Kimmel Cancer Center at Jefferson has shared a patent on what may someday be a ubiquitous tool in DNA analysis. The discovery could have a range of applications, from forensics to cloning to bioterrorism.

  • Peer Reviewed Publications (PubMed)
  • Selected Publications:
  • CostantinoCL, Witkiewicz AK, Kuwano Y, Cozzitorto JA, Kennedy EP, Dasgupta A, Keen JC, Yeo CJ, Gorospe M, Brody JR. HuRs role in gemcitabine efficacy in pancreatic cancer: HuR upregulates the expression of the gemcitabine metabolizing enzyme, deoxycytidine kinase. Cancer Research 2009 Jun 1;69(11):4567-7.
  • Brody JR, Witkiewicz AK, Yeo CJ, Gorospe M, Keen JC. The RNA-bindingome: future implications for chemotherapeutic efficacy. Future Oncology. 2009 Nov;5(9):1317-9.
  • Showalter SL, Showalter TN, Witkiewicz A, Havens R, Kennedy EP, Hucl T, Kern SE, Yeo CJ, Brody JR. Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil: Is it time to move forward? Cancer Biology and Therapy. 2008 Jul;7(7):986-94.
  • Brody JR, Hucl T, Gallmeier E, Winter JM, Kern SE, Murphy KM Genomic copy number changes affecting the TS gene in cancer: a model for patient classification to aid fluoropyrimidine therapy. Cancer Research 2006;66: 9369-9373.

Individual Expertise profile of Jonathan R Brody, Copyright © Jonathan R Brody.
Last Updated by Administration : Tuesday, February 22, 2011 11:20:18 AM

 Printable Version

Thomas Jefferson University
Thomas Jefferson University